Virgin coconut oil as adjunctive therapy for hospitalized COVID-19 patients in a Tertiary Referral Hospital: A randomized controlled trial
https://doi.org/10.47895/amp.vi0.7498
- Author:
Marissa M. Alejandria
1
,
2
;
Leslie Michelle M. Dalmacio
3
;
Fresthel Monica M. Climacosa
4
;
Carol Stephanie C. Tan-Lim
2
;
Mark Joseph M. Abaca
1
;
Maria Llaine J. Callanta
3
;
Maria Elizabeth P. Mercado
5
Author Information
1. Department of Medicine, Philippine General Hospital, University of the Philippines Manila
2. Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila
3. Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila
4. Department of Medical Microbiology, College of Public Health, University of the Philippines Manila
5. Department of Clinical Epidemiology, Faculty of Medicine and Surgery, University of Santo Tomas
- Publication Type:Journal Article
- Keywords:
Virgin coconut oil
- MeSH:
COVID-19;
Clinical Trial
- From:
Acta Medica Philippina
2024;58(8):31-41
- CountryPhilippines
- Language:English
-
Abstract:
Background:Virgin coconut oil (VCO) has anti-viral and anti-inflammatory properties, making it a potential therapeutic candidate against COVID-19 infection.
Objective:To determine the efficacy and safety of VCO as adjunctive therapy for hospitalized patients with COVID-19.
Methods:We conducted a randomized, open-label controlled trial involving laboratory-confirmed COVID-19 patients admitted at the Philippine General Hospital. The study participants were randomized to the intervention group who received virgin coconut oil with local standard of care, or to the control group who received local standard of care alone.
Results:We enrolled 39 participants into the VCO group and 38 participants into the control group. Significantly fewer participants in the VCO group had abnormal CRP levels at the end of treatment compared to control. (relative risk [RR] 0.75, 95% confidence interval [CI] 0.58 to 0.95; p=0.02) No significant difference was found in the duration of hospital stay (mean 9.33 days for VCO vs. 10.29 days for control; p=0.45) and time to symptom resolution (mean 6.8 days for VCO, vs. 6.74 days for control; p=0.91). Although the proportion of patients who developed the secondary outcomes of mortality, need for ICU admission, need for invasive ventilation, and negative viral conversion was lower in the VCO group, results did not reach statistical significance. The VCO group had larger reduction in the inflammatory markers ferritin, lactate dehydrogenase, TNF-alpha, IP-10 and IL-6, but results did not reach statistical significance. Adverse events were significantly higher in the VCO group (RR 4.87, 95% CI 1.14 to 20.79; p=0.03).
Conclusion:This clinical trial on hospitalized patients showed significant benefit in CRP levels of participants given VCO compared to control. There was no significant benefit in the use of VCO as adjunctive therapy in reducing duration of hospital stay. Larger studies are needed to conclusively demonstrate the effect of VCO on other clinical outcomes and inflammatory markers.
- Full text:20240607175738456567498-Article Text-116257-2-10-20240515.pdf
